Molecular biology enzymes are natural proteins produced by living organisms (animals, plants, and bacteria) and catalyze biological reactions associated with genetic material. Molecular biology regents are the chemicals used in the molecular biology reactions to optimize the workflow. Molecular biology kits comprise of enzymes and reagents and are used majorly for research and diagnostic applications.

The molecular biology enzymes and kits & reagents market is expected to reach USD 12.69 Billion by 2021 from USD 5.77 Billion in 2016, growing at a CAGR of 17.1% from 2016 to 2021. Growth of the molecular biology enzymes and kits & reagents market can be attributed to the technological advancements in the life science industry, increased research activities in the pharmaceutical & biotechnology sector, rising incidences of infectious diseases & genetic disorders, and successful completion of human genome project.

The molecular biology enzymes and kits & reagents market is segmented on the basis of product, application, and end user. By product, the molecular biology reagents market is categorized into kits & reagents and enzymes. The kits & reagents segment is expected to account for the largest share of the molecular biology reagents market in 2016. This segment is also estimated to grow at the faster rate during the forecast period. The larger share of this segment can be attributed to repeated use of reagents in the research activities and increasing usage of kits by hospitals and diagnostic centers backed by the rising incidence of genetic disorders.

The molecular biology enzymes and kit & reagents market, based on application, is segmented into PCR, sequencing, restriction digestion, cloning, epigenetics, and synthetic biology, among others. The PCR segment is expected to account for the largest share of the molecular biology reagents market in 2016. However, sequencing segment is expected to grow at the highest CAGR in the molecular biology enzymes and kits & reagents market, by application. Growth in this segment can be attributed to the increasing research activities involving genomic sequencing and decreasing cost of sequencing.

On the end user, the molecular biology enzymes and kit & reagents market is segmented into academic & research institutes, hospitals & diagnostic centers, and pharmaceutical & biotechnology companies, among others. The academic & research institutes segment is expected to account for the largest share of the molecular biology reagents market in 2016. The larger share of this segment is attributed to increasing research activities and availability of funds from government and private organization for the research in the field of molecular biology. However, hospitals & diagnostic centers segment is expected to grow at the highest CAGR in the molecular biology enzymes and kits & reagents market, by end user.

On the basis of regions, the molecular biology enzymes and kit & reagents market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the molecular biology kits market in 2016. The large share of North America can be attributed to increasing research funding in applied markets; rising number of pharmaceutical & biotechnology companies; increasing prevalence of conditions involving molecular diagnostics, backed by reimbursement in the U.S.; and investments into research projects in Canada. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period.

Source: Annual Reports, SEC Filings, Investor Presentations, Biotechnology and Biological Sciences Research Council, Department of Biotechnology, European Federation of Biotechnology, Genome Canada, National Human Genome Research Institute, World Bank, World Health Organization, World Intel lectual Property Organization, Expert Interviews, and MarketsandMarkets Analysis

The major players in the global molecular biology enzymes and kits & reagents market include Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), New England Biolabs, Inc. (U.S.), Promega Corporation (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Takara Bio, Inc. (Japan), and Becton, Dickinson and Company (U.S.).

They are established vendors with very strong business strategies. However, they have a weak product portfolio. They often specialize in certain products. Roche, Takara Bio, and PerkinElmer have been recognized as dynamic differentiators in this market.

Innovators are vendors that have demonstrated substantial product innovations as compared to their competitors. They have innovative products and the potential to build strong strategies for their business growth to be at par with the visionary leaders. Some of the innovators in this market are Agilent Technologies, Promega Corporation, Bioline, Jena Bioscience, and Molecular Biology Resources (MBR).